Business Monitor International


Cambodia Pharmaceuticals & Healthcare Report

Published 11 April 2014

  • 65 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Cambodia Pharmaceuticals & Healthcare Report
SWOT Analysis

Strengths

  • One of the more prominent local companies in the country.

  • Affiliated with CNN Generics Distribution.

Weaknesses

  • Strict price controls, with the government refocusing its efforts to reduce prices as a means to curb public-sector spending.

  • Inadequate access to medicines.

  • Branded medicines revenues suffering from effects of parallel import programmes.

Opportunities

  • Demand for medicines expected to rise as a result of ongoing healthcare sector modernisation.

  • Government's programme to provide universal healthcare insurance coverage by 2016.

  • ASEAN harmonisation to bring about significant positive changes in the market.

  • Positive economic performance with an increase in spending power to boost sector development.

Threats

  • Lax domestic patent law - with counterfeiting, lack of enforcement and poor data protection still problematic.

  • Strong competition in the relatively small market, with downward pressure on prices increasing.

Company Overview

Pacific Pharmaceutical Generics is one of the leading local pharmaceutical firms with around 300 products. It was established in 1949 as Pacific Insular Company, renaming itself as Pacific Pharmaceutical Generics in 1999. Most of its output is focused on generic products.

Strategy

Given that the majority of its output is focused on generic products, the company is theoretically well-placed to perform in the local market. However, competition from leading local players, namely Unilab and Pascual Labs, is intense, which may require some repositioning of its portfolio and a focus on niche areas. Its affiliation with the distributor CBB Generics should greatly facilitate such activities.

Recent Developments

Pacific Pharmaceutical Generics' product portfolio - of around 300 products - reaches some 3,000 clients nationwide, which is significant given the challenges posed to distribution activities due to the...

Table of Contents

BMI Industry View
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cambodia 2010-2018)
12
Healthcare Market Forecast
13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2010-2018)
14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2010-2018)
14
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2010-2018)
15
Pharmaceutical Trade Forecast
16
Table: Pharmaceutical Trade Data And Forecasts (Cambodia 2012-2018)
17
Table: Pharmaceutical Trade Data And Forecasts local currency (Cambodia 2012-2018)
17
Key Risks To BMI's Forecast Scenario
18
Industry Risk Reward Ratings
19
Asia Risk/Reward Ratings
19
Cambodia Risk/Reward Ratings
25
Rewards
25
Risks
26
Market Overview
27
Industry Trends And Developments
29
Epidemiology
29
Healthcare Sector
31
Health Insurance
32
Research & Development
33
Clinical Trials
33
Regulatory Development
35
Regulatory Regime
35
Intellectual Property Issues
35
Counterfeit Medicines
36
Pricing And Reimbursement
38
Competitive Landscape
39
Pharmaceutical Sector
39
Company Developments
41
Pharmaceutical Wholesale
42
Pharmaceutical Retail
42
Company Profile
44
PharmaProduct Manufacturing (PPM)
44
Cambodia Pharmaceutical Enterprise
47
Sanofi
49
Pfizer
52
Demographic Forecast
54
Table: Cambodia's Population By Age Group, 1990-2020 ('000)
55
Table: Cambodia's Population By Age Group, 1990-2020 (% of total)
56
Table: Cambodia's Key Population Ratios, 1990-2020
57
Table: Cambodia's Rural And Urban Population, 1990-2020
57
Glossary
58
Methodology
60
Pharmaceutical Expenditure Forecast Model
60
Healthcare Expenditure Forecast Model
60
Notes On Methodology
61
Risk/Reward Ratings Methodology
62
Ratings Overview
63
Table: Pharmaceutical Risk/Reward Ratings Indicators
63
Indicator Weightings
64

The Cambodia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Cambodia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Cambodian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Cambodia to test other views - a key input for successful budgeting and strategic business planning in the Cambodian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Cambodian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Cambodia.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc